Company news
Oric Pharmaceuticals, Inc. news in 2020
Oric Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101
December 20, 2020
ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
November 16, 2020
ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering
November 12, 2020
ORIC Pharmaceuticals Announces Proposed Public Offering of Common Stock
November 9, 2020
ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update
November 4, 2020
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program
October 18, 2020
ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020
October 8, 2020
ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update
August 4, 2020
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics
August 4, 2020
ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call
August 2, 2020
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II
June 21, 2020
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors
June 8, 2020
ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
May 26, 2020
ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference
May 25, 2020
ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
May 19, 2020
ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 27, 2020
ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting
April 26, 2020